Recommendations for the definition of clinical responder in insulin preservation studies

Diabetes

Volumn 63, Issue 9, 2014, Pages 3120-3127

  Beam, Craig A ^a   Gitelman, Stephen E ^b   Palmer, Jerry P ^c,d  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; INSULIN;

ADOLESCENT; ARTICLE; CELL FUNCTION; EUROPEAN MEDICINES AGENCY; FEMALE; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PANCREAS ISLET BETA CELL; PRESERVATION; PRIORITY JOURNAL;

ADOLESCENT; BIAS (EPIDEMIOLOGY); C-PEPTIDE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; MALE; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 84906657317     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-0095     Document Type: Article

References (25)

1. Committee for Medicinal Products for Human Use. Note for Guidance on the Clinical Investigation of Medicinal Products in the Treatment of Diabetes Mellitus. London, European Medicines Agency Report, 2012 (CPMP/EWP/1080/00 Rev. 1).
2. Office of Training and Communications, Division of Drug Information, Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Draft Guidance for Industry: Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention. 2008.
3. Harmonisation ICo. Harmonized Tripartite Guideline Statistical Principles for Clinical Trials: E9. Vol 63. Fed Regist 1998;49583.
4. Snapinn SM, Jiang Q. Responder analyses and the assessment of a clinically relevant treatment effect. Trials 2007;8:31.
5. Chiasson JL, Naditch L; Miglitol Canadian University Investigator Group. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. Diabetes Care 2001;24:989-994.
6. Luque Otero M, Martell Claros N; Study Investigators Group. Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study. Clin Ther 2005;27:166-173.
7. Shaibani A, Fares S, Selam JL, et al. Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial. J Pain 2009;10:818-828.
8. Uryniak T, Chan ISF, Fedorov VV, et al. Responder Analyses-A PhRMA Position Paper. Statistics in Biopharmaceutical Research 2011;3:476-487.
9. Palmer JP, Fleming GA, Greenbaum CJ, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004;53:250-264.
10. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003;26:832-836.
11. Lachin JM, McGee P, Palmer JP; DCCT/EDIC Research Group. Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes 2014;63:739-748.
12. Herold KC, Gitelman SE, Willi SM, et al. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 2013;56:391-400.
13. Herold KC, Pescovitz MD, McGee P, et al.; Type 1 Diabetes TrialNet Anti- CD20 Study Group. Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes. J Immunol 2011;187:1998-2005.
14. McGee P, Kraus-Steinrauf H, Greenbaum C, et al.; the Type I Diabetes TrialNet Study Group. Classification of a clinical responder for evaluation of treatment efficacy in trials of new-onset type 1 diabetes. Abstract presented at the 71st Scientific Sessions of the American Diabetes Association, 24-28 June 2011, San Diego, CA.
15. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al.; Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361:2143-2152.
16. Chesher A. The effect of measurement error. Biometrika 1991;78:451-462.
17. Oppenheimer L, Kher U. The impact of measurement error on the comparison of two treatments using a responder analysis. Stat Med 1999;18:2177-2188.
18. Greenbaum CJ, Beam CA, Boulware D, et al.; Type 1 Diabetes TrialNet Study Group. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 2012;61:2066-2073.
19. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, et al.; Type 1 Diabetes Trial Net Research Group; European C-Peptide Trial Study Group. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008;31:1966-1971.
20. Sherry N, Hagopian W, Ludvigsson J, et al.; Protégé Trial Investigators. Teplizumab for treatment of type 1 diabetes (Proté gé study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011;378:487-497.
21. Hagopian W, Ferry RJ Jr, Sherry N, et al.; Protégé Trial Investigators. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes 2013;62:3901-3908.
22. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
23. Fedorov V, Mannino F, Zhang R. Consequences of dichotomization. Pharm Stat 2009;8:50-61.
24. Goldberg JD. The effects of misclassification on the bias in the difference between two proportions and the relative odds in the fourfold table. J Am Stat Assoc 1975;70:561-567.
25. Mote VL, Anderson RL. An investigation of the effect of misclassification on the properties of chi-2-tests in the analysis of categorical data. Biometrika 1965; 52:95-109.